Over the past few years, the mastery of continuous production has opened particularly promising perspectives for pharmaceutical manufacturing. These proven methods enable the reduction of the time and cost of development, while ensuring a constant and robust manufacturing quality. Continuous production is therefore a major focus for health authorities that have been very proactive in this field, particularly with the publication of specific guidelines (ICH 13).
Since 2012, the TIPs laboratory (Transfer, Interface and Processes) at the Université Libre de Bruxelles has been involved in various R&D projects that have led to the development of new technologies related to flow control in milli/microfluidic structures.
To successfully complete this project, they teamed up with a business manager and two “legal and investment” profiles who also became co-founders of the company. The interest expressed by certain major players in the pharmaceutical industry for this “multitechnological” company capable of apprehending in a holistic way the complex issues of drug manufacturing quickly confirmed the pertinence of this project. The company hadn’t even been created yet when the first development contracts and equipment sales started being negotiated.
In 2018, the idea to give business value to these results within a single structure came to the mind of the future founders of Secoya, four researchers and one academic. Their objective? To offer innovative and unique solutions to the pharmaceutical industry by gathering complementary expertise and technologies within one single entity.
In October 2019, after raising funds from private investors, Secoya moved into its new headquarters gathering offices and laboratories within the scientific park of Louvain-la-Neuve, 20 minutes from Brussels. This is an ideal location, in the midst of a vibrant ecosystem of cutting-edge companies active in the fields of biotechnology and pharmaceuticals, and at the heart of a solid network of partners (precision mechanics, automation, engineering, imaging…) that is crucial to the development of its activities.